Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 13, 2012, Pages 4892-4897

  Wang, Yi ^a   Roche, Olga ^a   Xu, Chaoying ^a   Moriyama, Eduardo H ^b   Heir, Pardeep ^a   Chung, Jacky ^c   Roos, Frederik C ^a,d   Chen, Yonghong ^b   Finak, Greg ^e   Milosevic, Michael ^b   Wilson, Brian C ^b   Teh, Bin Tean ^f   Park, Morag ^e   Irwin, Meredith S ^c,g   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e MCGILL UNIVERSITY   (Canada)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA;

ARTICLE; CARCINOGENICITY; CAVEOLA; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION;

BASE SEQUENCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAVEOLAE; CAVEOLIN 1; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CONSERVED SEQUENCE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LIGANDS; MAP KINASE SIGNALING SYSTEM; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESPONSE ELEMENTS; RNA POLYMERASE II; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84859454686     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1112129109     Document Type: Article

References (52)

1. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
2. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
3. Kaelin WG, Jr. (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-682.
4. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:E83.
5. Roberts AM, Ohh M (2008) Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 20:83-89. (Pubitemid 350190986)
6. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246. (Pubitemid 41039148)
7. Parton RG, Simons K (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8:185-194.
8. Abulrob A, et al. (2004) Interactions of EGFR and caveolin-1 in human glioblastoma cells: Evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 23:6967-6979. (Pubitemid 39279997)
9. Tamaskar I, et al. (2007) Differential expression of caveolin-1 in renal neoplasms. Cancer 110:776-782. (Pubitemid 47257654)
10. Horiguchi A, et al. (2004) Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol 172:718-722. (Pubitemid 38900248)
11. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF (2008) Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 98:931-940. (Pubitemid 351341603)
12. Campbell L, Gumbleton M, Griffiths DF (2003) Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89:1909-1913. (Pubitemid 37533269)
13. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ (2004) Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 93:291-296. (Pubitemid 38253572)
14. Garcia E, Li M (2006) Caveolin-1 immunohistochemical analysis indifferentiating chromophobe renal cell carcinoma from renal oncocytoma. Am J Clin Pathol 125:392-398. (Pubitemid 43327708)
15. Carrion R, Morgan BE, Tannenbaum M, Salup R, Morgan MB (2003) Caveolin expression in adult renal tumors. Urol Oncol 21:191-196. (Pubitemid 36723706)
16. Karam JA, et al. (2007) Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67:614-622. (Pubitemid 46685281)
17. Yang G, Truong LD, Wheeler TM, Thompson TC (1999) Caveolin-1 expression inclinically confined human prostate cancer: A novel prognostic marker. Cancer Res 59:5719-5723.
18. Thompson TC (1998-1999) Metastasis-related genes in prostate cancer: The role of caveolin-1. Cancer Metastasis Rev 17:439-442.
19. Fong A, et al. (2003) Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am J Clin Pathol 120:93-100. (Pubitemid 37046375)
20. Murakami S, et al. (2003) Caveolin-I overexpression is afavourable prognostic factor for patients with extrahepatic bile duct carcinoma. Br J Cancer 88:1234-1238. (Pubitemid 36606339)
21. Shi L, Chen XM, Wang L, Zhang L, Chen Z (2007) Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: Correlation with vascular endothelial growth factor, microvessel density, and clinical outcome. Cancer 109:1523-1531. (Pubitemid 46595687)
22. Selga E, Morales C, Noé V, Peinado MA, Ciudad CJ (2008) Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 1:35.
23. Ho CC, et al. (2008) Caveolin-1 expression issignificantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 59:105-110.
24. Ando T, et al. (2007) The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep 18:601-609.
25. Savage K, et al. (2007) Caveolin 1is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13:90-101. (Pubitemid 46121857)
26. Yang G, et al. (1998) Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873-1880. (Pubitemid 28369170)
27. Burgermeister E, Liscovitch M, Röcken C, Schmid RM, Ebert MP (2008) Caveats of caveolin-1 in cancer progression. Cancer Lett 268:187-201.
28. Elvidge GP, et al. (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: The role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281:15215-15226. (Pubitemid 43855111)
29. Ohh M, et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427.
30. Wang Y, et al. (2009) Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 15:319-324.
31. Franovic A, et al. (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 104:13092-13097. (Pubitemid 351737598)
32. Wang Y, Ohh M (2010) Oxygen-mediated endocytosis incancer. J Cell Mol Med 14:496-503.
33. Sawano A, Takayama S, Matsuda M, Miyawaki A (2002) Lateral propagation of EGF signaling after local stimulation is dependent on receptor density. Dev Cell 3:245-257.
34. Yu X, Sharma KD, Takahashi T, Iwamoto R, Mekada E (2002) Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol Biol Cell 13:2547-2557. (Pubitemid 34831354)
35. Kondo K, Kaelin WG, Jr. (2001) The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 264:117-125. (Pubitemid 32989086)
36. Kondo K, et al. (2002) Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34:58-68. (Pubitemid 34260597)
37. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316. (Pubitemid 29473317)
38. O'Connor R (2003) Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 35:771-777.
39. Martinez-Outschoorn UE, et al. (2010) Autophagy incancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 9:3515-3533.
40. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP (1997) Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 272:6525-6533. (Pubitemid 27118133)
41. Lajoie P, et al. (2007) Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol 179:341-356. (Pubitemid 350004897)
42. Khan EM, et al. (2006) Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem 281:14486-14493. (Pubitemid 43848379)
43. Agelaki S, et al. (2009) Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther 8:1470-1477.
44. Tamaskar I, et al. (2007) Differential expression of caveolin-1 in renal neoplasms. Cancer 110:776-782. (Pubitemid 47257654)
45. Smith K, et al. (2005) Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 65:5221-5230. (Pubitemid 40827332)
46. Agelaki S, et al. (2009) Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther 8:1470-1477.
47. Motzer RJ, et al. (2010) Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 33:614-618.
48. Cella D, et al. (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial. J Clin Oncol 26:3763-3769.
49. Niemeyer CM, et al. (2010) Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 42:794-800.
50. Hoffman MA, et al. (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027. (Pubitemid 32447779)
51. Lonergan KM, et al. (1998) Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732-741. (Pubitemid 28063406)
52. Maxwell PH, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275. (Pubitemid 29246458)